A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

• Status: Recruiting
• Trial end date: 2022-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is being done to evaluate the safety, tolerability and effectiveness of Oral CG-806 for the treatment of patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or Non-Hodgkin's Lymphomas who have failed or are intolerant to two or more lines of established therapy or for whom no other treatment options are available.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Aptose Biosciences Inc.

Criteria

Inclusion Criteria:

• Age ≥ 18 years

• Life expectancy of at least 2 months

• ECOG Performance Status ≤ 2

• Patients must be able to swallow capsules

• Adequate hematologic parameters, unless cytopenias are disease caused

• Adequate renal, liver and cardiac function parameters

Exclusion Criteria:

• Patients with GVHD requiring systemic immunosuppressive therapy

• Uncontrolled leptomeningeal disease, auto-immune hemolytic anemia and uncontrolled and clinical significant disease related metabolic disorder

• Clinically significant intravascular coagulation

• Treatment with other investigational drugs within 14 days prior to first study treatment administration